Articles about aespironics appeared in the October editions of both
European Medical Device Manufacturer and Inhalation Magazine.

The major German television channel RTL broadcast an item on aespironics, showing the company's laboratory and interviewing Prof. Dan Adler.

Frost & Sullivan's prestigious Technical Insights service has initiated coverage of aespironics with the publication of a very positive "Medical Device Technology Alert" covering aespironics' technology and initial product design. This newsletter goes to Frost & Sullivan's subscriber base of decision makers in the medical industry.

The London DPI conference is one of two major annual industry events in the DPI industry. This year aespironics was invited to present a lecture on its technology. The presentation was very well received.

The company has successfully completed testing the fine particle fraction (FPF) and emitted dose achieved when using aespironics' test rig to emulate the inhalation process. A number of powders i ncluding drugs were tested, and in all cases the results proved that the company's technology enables very-high performance single-dose inhalers to be implemented.

The company has completed its test rig set up, enabling it to test the company's "active mesh" operating principle on a range of device designs and a range of different powders. The test rig includes an artificial lung capable of accurately reproducing any inspiration profile, and a Malvern particle analyzer.

Every year the Israel Life Science Industry (ILSI) association runs a competition to choose the outstanding new ventures in the life science field. At this year's award ceremony, aespironics received second place.

Maayan Ventures, the seed fund arm of the major Israeli VC fund Infinity placed the seed investment round in aespironics. The funds were matched by the Israeli Ministry of Science and Industry.